Sanofi inks deal with I-Mab; Wave discloses $175M offering on heels of DMD data
Plus, news about BioAge, Fulcrum Therapeutics and Arcutis Biotherapeutics: Sanofi snags Greater China rights to CD73 antibody: The French pharma will pay TJ Biopharma €32 million (or about $35 million)...
View Article#EADV24: Novo's semaglutide shows potential in chronic skin condition in...
A small study conducted by researchers at St. Vincent’s University Hospital in Dublin suggests that Novo Nordisk’s GLP-1 semaglutide could treat a common and chronic skin condition called hidradenitis...
View ArticleCelldex reveals Phase 2 responses for chronic hives drug and higher rates of...
Celldex Therapeutics has unveiled 52-week results from a mid-stage study of its anti-KIT drug in chronic hives, raising anticipation for ongoing registrational studies. But the company’s shares $CLDX...
View ArticleClik here to view.
Emergent says it has $400M in orders related to mpox outbreak
Emergent BioSolutions has secured around $400 million worth of orders for its smallpox and monkeypox products, including its vaccine being used to help protect against a mpox outbreak in Africa. The...
View ArticleBaltimore sues Biogen, saying the company colluded with PBMs to minimize...
Baltimore’s mayor and city council have sued Biogen, alleging that the Boston-based drug developer worked with pharmacy benefit managers to suppress generic versions of a popular multiple sclerosis...
View ArticleEMA to discuss Pfizer's sickle cell drug Oxbryta after patient deaths
The European Medicines Agency will meet on Thursday to discuss Oxbryta — the sickle cell treatment Pfizer inherited in its $5.4 billion acquisition of Global Blood Therapeutics — following patient...
View ArticleUK watchdog criticizes Moderna for Covid-19 trial's use of WhatsApp to dangle...
The UK’s pharma marketing watchdog, the Prescription Medicines Code of Practice Authority, is taking issue with the way Moderna allegedly sought to increase participation in a Covid-19 vaccine trial...
View ArticleJ&J folds cardiovascular and metabolic drug unit
Johnson & Johnson is winding down its pharma division’s cardiovascular and metabolic unit, Endpoints News has learned. The decision primarily impacts the sales, marketing and medical affairs teams,...
View ArticleClik here to view.
Pfizer pulls sickle cell drug from all markets after data review showed rise...
Pfizer said it will withdraw its sickle cell disease treatment Oxbryta from all markets worldwide, after data showed an “imbalance” of fatalities and complications common to the disease. The surprise...
View ArticleNext-gen obesity biotech BioAge Labs to raise $198M in IPO
A California biotech that began as an anti-aging company, then licensed an Amgen heart failure drug for $1 million upfront and repurposed it as a weight loss therapy, has lined up a $198 million IPO....
View ArticleBarcelona VC firm Asabys raises second fund, adding to Europe’s biotech...
Asabys Partners said Thursday it closed its second health innovation fund at €180 million, or about $200 million. The Barcelona-based VC firm’s raise expands the money available to biotech and health...
View ArticleClik here to view.
Flagship launches startup to design and make lipid nanoparticles for genetic...
Flagship Pioneering is betting $50 million that it can solve one of genetic medicine’s biggest problems — how to get the therapies to the right place in the body. Its new startup, Mirai Bio, was...
View ArticleClik here to view.
EnGene unveils first set of pivotal data for NMIBC therapy
A small US and Canadian gene therapy biotech has released a look at data from its experimental bladder cancer treatment, hoping to enter a field that includes CG Oncology, ImmunityBio, Johnson &...
View ArticleBiogen walks away from Sage's essential tremor drug after mid-stage flop,...
Biogen is saying goodbye to part of its tie-up with Sage Therapeutics after the duo’s experimental medicine failed a Phase 2 essential tremor study this summer. That July flop left the drug’s future up...
View ArticleClik here to view.
Merck, Evaxion expand collaboration with infectious disease vaccine pact
Merck has inked an option and license agreement with Evaxion Biotech for two of its AI-designed vaccine candidates, bolstering an existing relationship between the drugmakers. Under Thursday’s deal,...
View ArticleA Parkinson's drug that AbbVie acquired from Cerevel succeeds in another Phase 3
AbbVie once again reported positive Phase 3 data for a Parkinson’s disease drug that was acquired from its Cerevel buyout, this time as a monotherapy. Topline data show that both doses of tavapadon...
View ArticleARCH, biotech's star slugger, snags another $3B for 13th fund
Bob Nelsen will tell you that ARCH Venture Partners is always chasing home runs. The early-stage VC firm has backed some of the most recognizable names in drug development, like Alnylam, bluebird bio...
View ArticleCSL Seqirus inks fifth contract with BARDA, making the partnership now worth...
CSL Seqirus has secured a fresh $121.4 million contract with the US Biomedical Advanced Research and Development Authority to manufacture and supply its adjuvanted vaccine against avian flu, bringing...
View ArticleClik here to view.
Instacart partners with 9amHealth to combine weight loss drugs with healthy...
The GLP-1 prescription startup 9amHealth is partnering with grocery delivery service Instacart to incorporate stipends for healthy foods into its treatment plans for diabetes, weight loss and heart...
View ArticleRepair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M
Plus, news about Enanta, Inventiva, Eradivir, Novo Nordisk, Evotec, Lundbeck, Iambic Therapeutics and Wave Life Sciences: Genevant Sciences, Repair Biotechnologies team up: The biotechs will work on a...
View Article